CIPLA
Back to Cashflow Statement
|
CIPLA Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|---|---|
Cash Flow from Financing Activities | ₹-1,293 Cr | ₹-1,200 Cr | ₹-958 Cr | ₹-1,600 Cr | ₹-1,240 Cr |
What is the latest Cash Flow from Financing Activities ratio of CIPLA ?
Year | Cash Flow from Financing Activities |
---|---|
Mar2025 | ₹-1,293 Cr |
Mar2024 | ₹-1,200 Cr |
Mar2023 | ₹-958 Cr |
Mar2022 | ₹-1,600 Cr |
Mar2021 | ₹-1,240 Cr |
How is Cash Flow from Financing Activities of CIPLA Trending?
Years | Cash Flow from Financing Activities | % Change | |
---|---|---|---|
Mar2025 | ₹-1,293 Cr | Negative | |
Mar2024 | ₹-1,200 Cr | Negative | |
Mar2023 | ₹-958 Cr | Negative | |
Mar2022 | ₹-1,600 Cr | Negative | |
Mar2021 | ₹-1,240 Cr | - |
Compare Cash Flow from Financing Activities of peers of CIPLA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
CIPLA | ₹121,266.9 Cr | -4.4% | -0.5% | 0.7% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹390,864.0 Cr | -4.3% | -3% | -0.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹168,811.0 Cr | -3.3% | -7.4% | 34.1% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹124,352.0 Cr | 1.4% | 10.1% | 17.9% | Stock Analytics | |
MANKIND PHARMA | ₹105,753.0 Cr | 0.8% | 8.4% | 26.4% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹101,786.0 Cr | -5.2% | -5.7% | -5.9% | Stock Analytics |
CIPLA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
CIPLA | -4.4% |
-0.5% |
0.7% |
SENSEX | -1.1% |
-3.4% |
-1.1% |
You may also like the below Video Courses